Oliver von Richter, PhD, FCP

Oliver is a pharmacist, trained at Schools of Pharmacy in Mainz, Germany and Dijon, France. He received his PhD in 2000 from the Margarete Fischer-Bosch Institute for Clinical Pharmacology in Stuttgart followed by a PostDoc in Pharmacogenetics at the Karolinska Institute in Stockholm.

Oliver started his career in non-clinical DMPK supporting lead finding, lead optimization and candidate selection in 2001 joining Altana Pharma in Konstanz, Germany. In 2005 he transitioned to clinical development integrating biomarkers and pharmacogenetics within the department of Exploratory Medicine. In 2007, he became Head of Pharmacokinetics & Pharmacometrics at AiCuris GmbH, responsible for non-clinical PK and supporting early clinical development of antiviral drugs. Oliver joined the department of Clinical Pharmacology at MerckSerono in January 2010 engaged in early clinical development of anticancer drugs. Since 2015 Oliver works for the department of Clinical Pharmacology at Sandoz Biopharmaceuticals.

He and his teams contributed to early clinical development of the MEK 1/2 inhibitor pimasertib and the HCMV terminase inhibitor letermovir, as well as to international regulatory approval of Roflumilast, a “first-in-class” PDE4 inhibitor.

Oliver has published more than 30 peer-reviewed articles and 1 book chapter related to non-clinical/ clinical drug development, clinical pharmacology and pharmacogenetics (h-index: 23; RG-score 32.4). In 2001, he was awarded the Prix Galien, for contributing to the discovery of the ABCB1 C3435T polymorphism. Oliver is a fellow of the American College of Clinical Pharmacology and a co-founder and Faculty Member of the International Marbach Castle Drug- Drug Interaction Workshop series that was established in 2010.